Education
About Us
Working with TipRanks
Follow Us
Fuso Pharmaceutical Industries,Ltd. (JP:4538)
:4538
4538 Stock Chart & Stats
¥2315.00
-¥64.00(-2.54%)
At close: 4:00 PM EST
¥2315.00
-¥64.00(-2.54%)
Day’s Range― - ―
52-Week Range¥2,028.00 - ¥2,641.00
Previous CloseN/A
Volume28.90K
Average Volume (3M)17.49K
Market Cap
¥21.93B
Enterprise Value¥43.86B
Total Cash (Recent Filing)¥3.16B
Total Debt (Recent Filing)¥28.23B
Price to Earnings (P/E)5.8
Beta0.61
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.71%
Share Statistics
EPS (TTM)99.84
Shares Outstanding9,451,169
10 Day Avg. Volume18,340
30 Day Avg. Volume17,486
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.53
Price to Sales (P/S)0.34
P/FCF Ratio-3.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthFuso delivered a 9.31% revenue increase year-over-year, indicating steady demand for its hospital-use pharmaceuticals. Sustainable top-line growth supports reinvestment in manufacturing and R&D, and suggests durable end-market position among hospital and clinical customers over the next 2-6 months.
Stable Gross And Net MarginsGross margin of 27.3% with net margin improving to 4.59% reflects persistent pricing power or efficient cost control in manufacturing and distribution. Margin stability provides a buffer for profitability through demand cycles and supports medium-term ability to fund operations and targeted investments.
Prudent Balance Sheet LeverageA debt-to-equity ratio of 0.54 and near-50% equity ratio indicate conservative leverage and a strong equity base. Manageable debt levels increase financial flexibility for capex or strategic moves, lowering refinancing risk and supporting stability across economic cycles.
Bears Say
Negative Free Cash FlowMaterial negative free cash flow (-5.43bn JPY) and a negative operating cash flow to net income ratio show the company struggles to convert profits into cash. This weakens ability to sustain capex, dividends, or fund growth internally, potentially forcing external financing or cuts.
Moderate Operating MarginsEBIT and EBITDA margins in the mid-single digits to low double digits highlight limited operating leverage versus peers. Moderate margins constrain internal cash generation and reduce the headroom to absorb cost inflation or fund higher R&D intensity needed for long-term product competitiveness.
Large EPS Volatility/declineA deeply negative EPS growth reading indicates pronounced earnings volatility or a significant EPS contraction year-over-year. Such swings undermine predictability of profitability and complicate longer-term planning for investment, dividend policy, and capital allocation decisions.
Fuso Pharmaceutical Industries,Ltd. News
4538 FAQ
What was Fuso Pharmaceutical Industries,Ltd.’s price range in the past 12 months?
Fuso Pharmaceutical Industries,Ltd. lowest stock price was ¥2028.00 and its highest was ¥2641.00 in the past 12 months.
What is Fuso Pharmaceutical Industries,Ltd.’s market cap?
Fuso Pharmaceutical Industries,Ltd.’s market cap is ¥21.93B.
When is Fuso Pharmaceutical Industries,Ltd.’s upcoming earnings report date?
Fuso Pharmaceutical Industries,Ltd.’s upcoming earnings report date is May 13, 2026 which is in 65 days.
How were Fuso Pharmaceutical Industries,Ltd.’s earnings last quarter?
Fuso Pharmaceutical Industries,Ltd. released its earnings results on Feb 12, 2026. The company reported ¥99.84 earnings per share for the quarter, beating the consensus estimate of N/A by ¥99.84.
Is Fuso Pharmaceutical Industries,Ltd. overvalued?
According to Wall Street analysts Fuso Pharmaceutical Industries,Ltd.’s price is currently Overvalued.
Does Fuso Pharmaceutical Industries,Ltd. pay dividends?
Fuso Pharmaceutical Industries,Ltd. pays a Semiannually dividend of ¥45 which represents an annual dividend yield of 3.71%. See more information on Fuso Pharmaceutical Industries,Ltd. dividends here
What is Fuso Pharmaceutical Industries,Ltd.’s EPS estimate?
Fuso Pharmaceutical Industries,Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fuso Pharmaceutical Industries,Ltd. have?
Fuso Pharmaceutical Industries,Ltd. has 9,451,169 shares outstanding.
What happened to Fuso Pharmaceutical Industries,Ltd.’s price movement after its last earnings report?
Fuso Pharmaceutical Industries,Ltd. reported an EPS of ¥99.84 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.465%.
Which hedge fund is a major shareholder of Fuso Pharmaceutical Industries,Ltd.?
Currently, no hedge funds are holding shares in JP:4538
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fuso Pharmaceutical Industries,Ltd.
Fuso Pharmaceutical Industries,Ltd. manufactures and sells pharmaceutical products in Japan. The company offers ethical drugs, such as injectables and artificial kidney dialysates; and medical machinery and equipment. It also rents real estate properties. The company was founded in 1937 and is headquartered in Osaka, Japan.
Technical Analysis
Pharma Foods International Co., Ltd.
―
Wakamoto Pharmaceutical Co., Ltd.
―
Morishita Jintan Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Options Prices
Currently, No data available
---